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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.031Classical immunohistochemical studies in the Alzheimer disease (AD) brain reveal prominent glial reac-
tions, but whether this pathological feature is due primarily to cell proliferation or to a phenotypic change
of existing resting cells remains controversial. We performed double-ﬂuorescence immunohistochemical
studies of astrocytes and microglia, followed by unbiased stereology-based quantitation in temporal
cortex of 40 AD patients and 32 age-matched nondemented subjects. Glial ﬁbrillary acidic protein (GFAP)
and major histocompatibility complex II (MHC2) were used as markers of astrocytic and microglial acti-
vation, respectively. Aldehyde dehydrogenase 1 L1 and glutamine synthetase were used as constitutive
astrocytic markers, and ionized calcium-binding adaptor molecule 1 (IBA1) as a constitutive microglial
marker. As expected, AD patients had higher numbers of GFAPþ astrocytes and MHC2þ microglia than the
nondemented subjects. However, both groups had similar numbers of total astrocytes andmicroglia and, in
the AD group, these total numbers remained essentially constant over the clinical course of the disease.
The GFAP immunoreactivity of astrocytes, but not the MHC2 immunoreactivity of microglia, increased in
parallel with the duration of the clinical illness in the AD group. Cortical atrophy contributed to the
perception of increased glia density. We conclude that a phenotypic change of existing glial cells, rather
than a marked proliferation of glial precursors, accounts for the majority of the glial responses observed in
the AD brain. (Am J Pathol 2013, 182: 2332e2344; http://dx.doi.org/10.1016/j.ajpath.2013.02.031)Supported by NIH grants AG08487 and P50-AG05134 (to B.T.H.).
A.S.-P. was awarded a fellowship from Fundación Alfonso Martín Escu-
dero (Madrid, Spain).The role of glial cells in Alzheimer disease (AD), particularly
the role of astrocytes and microglia, is a matter of growing
interest. Pioneering immunohistochemical studies revealed
an increased immunoreactivity for astrocytes and microglial
cells in the cortex of AD patients, compared with that of
nondemented elderly people, with the vast majority of these
cells clustering around dense-core plaques.1,2 Astrocytes are
usually visualized with immunohistochemistry for glial
ﬁbrillary acidic protein (GFAP), but recent data suggest that
only a subset of all astrocytes, labeled with aldehyde dehy-
drogenase 1 L1 (ALDH1L1), are also GFAP immuno-
positive.3,4 Similarly, a number of microglial markers are
available that do not completely overlap with one another and
that also label blood and bone marrow mononuclear phago-
cytes,5 including major histocompatibility complex II
[MHC2 (alias HLA-DP-DQ-DR)],6 CD11b (alias Mac-1,
CR3),7 CD45 [alias leukocyte common antigen (LCA)],8
ionized calcium-binding adaptor molecule 1 [IBA1; alias
allograft inﬂammatory factor 1 (AIF-1)],9 and CD68.10stigative Pathology.
.In AD, in various other neurodegenerative disorders, and in
acute brain injuries such as stroke, trauma or infection, the
terms reactive astrocytes and activated microglia are widely
used to describe the characteristic morphology (ie, hyper-
trophy of soma and retraction and thickening of processes) of
these glial cells. However, the astrocytic and microglial
reactions observed in these conditions have also been often
referred to as glial proliferation or glial hyperplasia.11,12 To
understand the role of glial cells in AD and their relationship
to amyloid plaques and neuroﬁbrillary tangles (NFTs), the
pathological hallmarks ofAD, it is important to knowwhether
glial responses involve proliferation of glia or are due mainly
to a phenotypic change in existing glia. With the present
study,we sought to understand the relative contribution of cell
proliferation versus phenotypic change to the increased
Table 1 Clinicodemographic Characteristics of Study Subjects
Characteristic Nondemented AD P value
Sample size n Z 32 n Z 40
Age at death [years
(means  SD)]
81.3  12.6 77.6  8.6 >0.05*
Females [no. (%)] 19 (59.4) 26 (65.0) >0.05y
Postmortem interval
[hours (means  SD)]
17.9  11.7 14.1  6.2 >0.05z
APOE ε4 allele carriers
[n/N (%)]
5/27x (18.5) 21/40 (52.5) 0.0058y
*Unpaired Student’s t-test with Welch’s correction.
yChi-square with Fisher’s exact test.
zU-test.
xAPOE genotype was not available for ﬁve nondemented subjects.
Phenotypic Change of Glia in ADnumber of astrocytes andmicroglial cells described in the AD
brain by classical immunohistochemistry.
To this end, we performed double-ﬂuorescence immuno-
histochemical studies and unbiased stereology-based anal-
yses on the temporal cortex of a large sample of AD patients
and age-matched nondemented individuals. Double-labeling
of astrocytes with GFAP and glutamine synthetase (GS) or
ALDH1L1 enabled the visualization of many astrocytes that
were not identiﬁable with GFAP immunohistochemistry
alone, particularly in nondemented subjects. Stereology-
based counts revealed that the total number of astrocytes
does not differ between AD brain and normal aging brain, and
that the number of astrocytes remains essentially constant
through the clinical course of AD (although astrocytes
increasingly become GFAPþ as the disease progresses).
Double-labeling of microglia with IBA1 andMHC2 revealed
that there are distinct subpopulations of microglial cells in the
cortex, and that the number of MHC2þ activated microglia,
but not the total number of microglial cells, is signiﬁcantly
increased in the AD brain. Thus, we conclude that glial
responses in AD are largely due to a phenotypic change of
resting glial cells, rather than to cell proliferation.
Materials and Methods
Subjects
Clinicodemographic characteristics of the study subjects are
summarized in Table 1. Brain specimens of 40 AD patients
and 32 nondemented individuals were obtained from the
Massachusetts Alzheimer’s Disease Research Center brain
bank. The 40 AD patients met clinical criteria for probable
AD13 and neuropathological criteria for high likelihood of
AD,14 and were selected on the basis of disease duration from
symptom onset (5 years, n Z 10; 6 to 10 years, n Z 10;
11e15 years, n Z 10; >15 years, n Z 10). The 32 non-
demented control subjects had no clinical history of neuro-
logical disorders and did not meet the pathological criteria for
any neurodegenerative disease.
Morphological Studies
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded sections (8 mm thick)
from the temporal polar association cortex (Brodmann area
38) were cleared in xylenes, rehydrated with decreasing
concentrations of ethanol, and subjected to a standard antigen-
retrieval procedure consisting of a 20minutesmicrowaving in
boiling citrate buffer (0.01 mol/L, pH 6.0) with 0.05% Tween
20. The sections were cooled at 4C for approximately 30 to
45 minutes, blocked with 5% normal goat serum at room
temperature for 1 hour, and incubated with the primary anti-
body overnight at 4C. The next day, the sections were
washed three times (for 10 minutes each wash) with Tris-
buffered saline and incubated with the appropriate secondary
antibodies for 1 hour at room temperature. Finally, theThe American Journal of Pathology - ajp.amjpathol.orgsections were again washed three times (for 10 minutes each
wash) with Tris-buffered saline, incubated with DAPI
(catalog no. MP01306; Life TechnologieseInvitrogen,
Carlsbad, CA) for 20 minutes to display the cell nuclei,
counterstained with Thioﬂavin-S 0.05% in ethanol 50% for
8 minutes, differentiated in ethanol 80% for 30 seconds, and
then coverslipped with Immu-Mount nonﬂuorescing aqueous
mountingmedium (catalog no. 99-904-12; ThermoScientiﬁc,
Pittsburgh, PA) or ProLongGold antifade reagent (catalog no.
P36934; Life TechnologieseInvitrogen).
To label astrocytes, rabbit polyclonal anti-GFAP (1:1000;
catalog no. G9269; Sigma-Aldrich, St. Louis, MO) was
combined with either mouse monoclonal anti-ALDH1L1
(1:50 supernatant; catalog no. 73-164; NeuroMab, UCDavis,
Davis, CA) or mouse monoclonal anti-GS (1:1000; clone
GS-6, catalog no. MAB302; EMDMillipore, Billerica, MA).
Fluorescently labeled secondary antibodies used were Cy3e
conjugated goat anti-rabbit and Alexa Fluor 488econjugated
goat anti-mouse (both 1:200; Jackson ImmunoResearch
Laboratories, West Grove, PA).
For study of microglia, rabbit polyclonal anti-IBA1 anti-
body (1:250; catalog no. 019-19741; Wako Pure Chemical
Industries, Osaka, Japan) was combined with mouse mo-
noclonal antieHLA-DP-DQ-DR antibody (1:100; clone
CR3/43, catalog no. M0775; Dako, Carpinteria, CA). Sec-
ondary antibodies were Alexa Fluor 488econjugated goat
anti-rabbit and Cy3-conjugated goat anti-mouse (both 1:200;
Jackson ImmunoResearch Laboratories). To minimize
autoﬂuorescence and facilitate the quantitative analysis of
microglial cells, the sections doubly stained for IBA1 and
MHC2 were treated with an autoﬂuorescence eliminator
reagent (catalog no. 2160; EMD Millipore) according to the
manufacturer’s instructions. Sections not incubated with the
primary antibodies served as a negative control in both im-
munohistochemical studies.
The mitotic marker Ki-67 was used to investigate cell
proliferation. Ki-67 is a nuclear protein that is not expressed
during the G0 phase but is up-regulated throughout the cell
cycle and, thus, unlike cyclins, can label cells in all G1, S,
and G2 phases.15 The Ki-67 antibody (1:50; rabbit mono-
clonal, clone SP6; catalog no. ab16667; Abcam, Cambridge,2333
Serrano-Pozo et alMA) was used in temporal cortex and hippocampal sections
pretreatedwith the antigen-retrieval protocol described above.
This antigen-retrieval method has been reported to be very
effective for improving the Ki-67-immunoreactive signal in
formalin-ﬁxed, parafﬁn-embedded archival tissue, even when
the parafﬁn blocks have been stored for up to 60 years.16 After
immunohistochemistry, the sections were treated with the
same autoﬂuorescence eliminator reagent (EMD Millipore).
Sections from an autopsied patient with a high-grade glioma
were used as a positive control.
Stereology-Based Quantitative Analyses
Stereology-based studies were performed in single sections
per case. Sections were placed on the motorized stage of an
Olympus BX51 epiﬂuorescence microscope equipped with
a DP70 digital CCD camera, an X-Cite ﬂuorescent lamp, and
the associated CAST stereology software version 2.3.1.5
(Olympus, Tokyo, Japan). The cortical ribbon of the spec-
imen was outlined with the appropriate tool of this software
under the 4 objective, and this region of interest was
randomly sampled using the optical disector probe of the
software. For astrocytes, the stereology-based counts were
performed under the 20 objective, with a meander sampling
of 1% and a counting frame of 14,260 mm2 area (10%). For
microglia, we used a 40 objective, a meander sampling of
1% to 4%, and a counting frame of 3565 mm2 area (10%). The
random sampling protocol was designed to cover the entire
cortical ribbon of the specimen with an even representation of
the six cortical layers and with an endpoint of at least 100
cells. A dual-band ﬁlter cube ﬂuorescein isothiocyanate/Cy3
(U-N51009; Chroma Technology, Brattleboro, VT) designed
for the simultaneous visualization of these two ﬂuorophores
was used to examine immunoreactivity for the pairs of
astrocytic or microglial markers mentioned above.
Only glial cells with the cell soma and DAPI-positive
visible nucleus inside the counting frame or outside but
touching either of the two green sides were counted; those
with the cell soma touching either of the red sides of the
counting frame were excluded from the count. During quan-
tiﬁcation of microglia, cells immunoreactive for IBA1 or
MHC2 that were located within vessels or in their immediate
vicinity were interpreted as blood mononuclear phagocytes
and perivascular macrophages, respectively, and were not
counted. The distance between each microglial cell and the
closest Thioﬂavin-Sepositive dense-core plaque or NFT was
obtained with the appropriate tool of the CAST software, and
microglial cells were then classiﬁed as close, if located within
50 mm, or as far, if located beyond this boundary.
Counts were performed under masking to clinical data
(diagnosis, disease duration, APOE genotype). The density
of astrocytes and of microglial cells was calculated as the
number of cells of each type counted, divided by the total area
sampled (number of disectors  counting frame size). To
prevent the enhancing effect of disease-related cortical atrophy
on density values in the AD group, these values were then
corrected by the average cortical thickness of the specimen and2334normalized to a 1 cm-long strip of full-width cortex to obtain
a total number of astrocytes and microglial cells.
The cortical thickness was obtained as described previ-
ously.17 Brieﬂy, sections were placed under the 1.6 objec-
tive of the microscope and the full thickness of the cortical
ribbon was measured with the appropriate tool of the CAST
software in 20 random sites throughout the specimen. Cortical
thickness was estimated as the average of these 20
measurements.
Statistical Analysis
Normality of data sets was evaluated with the D’Ag-
ostinoePearson omnibus test. Pairwise comparisons were
performed with a U-test when either of the two data sets was
not normally distributed, and with an unpaired Student’s
t-test when both were normally distributed. In the latter,
Welch’s correction was applied when the variances were
signiﬁcantly different according to the F-test. Correlations
between number of astrocytes or microglial cells and disease
duration, age of death, and postmortem interval were per-
formed with Pearson’s correlation test or with Spearman’s
sum rank correlation, when appropriate. Comparisons bet-
ween microglia counts close to and far from plaques and
NFTs were performed with a one-tailed Wilcoxon signed
rank test or a one-tailed paired t-test, when appropriate. All
other tests were two-sided. The signiﬁcance level was set at
P < 0.05. All statistical analyses were performed using
GraphPad Prism for Mac software version 5.0 (GraphPad
Software, La Jolla, CA).
Results
Phenotypic Change But Constant Number of Astrocytes
in AD
To investigate whether the enhanced GFAP immunoreac-
tivity observed in AD is due to astrocyte proliferation or
whether it indicates a phenotypic change from resting
GFAP astrocytes to reactive GFAPþ astrocytes, we per-
formed double-ﬂuorescence immunostaining for GFAP and
ALDH1L1 in the temporal association cortex of 40 AD
patients and 32 nondemented control subjects. ALDH1L1 is
a glycolytic enzyme isoform expressed mainly in astro-
cytes.3,4 Preliminary inspection revealed that ALDH1L1
positivity is useful for detecting many astrocytes that would
be otherwise undetectable with GFAP immunostaining
alone, particularly in nondemented control subjects; in the
AD group, as expected, most astrocytes were also GFAPþ
(Figure 1). Thus, we distinguished two main populations of
astrocytes: ALDH1L1þGFAP (resting astrocytes) and
ALDH1L1þGFAPþ (reactive astrocytes).
Using unbiased stereology-based quantitation, we
observed that the total number of astrocytes did not differ
signiﬁcantly between the nondemented and the AD groups
(P Z 0.3616) (Figure 2A). As expected, the number ofajp.amjpathol.org - The American Journal of Pathology
Figure 1 Confocal images representative of double-ﬂuorescence immunohistochemical study of astrocytes with ALDH1L1 (green) (AeD) and GFAP (red)
(EeH); merged images are also shown (IeL). Representative images from four cases are shown: one nondemented control subject (A, E, and I), and three AD
patients with 5 years (B, F, and J), 12 years (C, G, and K), and 19 years (D, H, and L) of clinical illness. The majority of astrocytes in the nondemented
individual were GFAP (resting astrocytes), as seen in the merged image (I), whereas astrocytes in the AD cortex displayed a reactive phenotype with GFAP-
immunoreactivity that was associated with the duration of the illness (J, K, and L). Disease-related cortical atrophy produced an increase in the density of
astrocytes (green) (A versus D). Scale bar Z 50 mm.
Phenotypic Change of Glia in ADreactive GFAPþ astrocytes was much higher in the AD group
(PZ 0.0082) (Figure 2E). By contrast, the number of resting
ALDH1L1þGFAP astrocytes was substantially lower (PZ
0.0033) (Figure 2C). To evaluate whether these changes track
with disease severity, we performed correlations between cell
counts and disease duration from symptom onset within the
AD group. We have previously used disease duration from
symptom onset as a reliable proxy of dementia severity inAD.
Disease duration has the advantage of avoiding theﬂoor effect
of neuropsychological testing in patients with severe de-
mentia, who are typically not testable. Furthermore, in our
previous neuropathological studies we have observed that
disease duration correlates with the burden of NFTs18 and
with the extent of neuron loss,19 synaptic loss,20 and cortical
atrophy,21 which are the strongest pathological correlates of
cognitive decline in AD. Moreover, unlike categorical vari-
ables such as Braak stage of NFTs, duration of illness is
inherently a continuous linear variable. The correlations with
duration of clinical illness revealed that the number of
ALDH1L1þGFAPþ reactive astrocytes increased linearly
(rZ 0.4768, PZ 0.0019) (Figure 2F), just as the number of
ALDH1L1þGFAP resting astrocytesdecreased (rZ0.4884,The American Journal of Pathology - ajp.amjpathol.orgPZ 0.0014) (Figure 2D), but the total number of astrocytes
remained essentially unchanged after symptom onset, despite
disease progression (rZ 0.2276, PZ 0.1579) (Figure 2B).
We sought to conﬁrm these results with another astrocytic
marker, GS. This enzyme catalyzes the conversion of gluta-
mate into glutamine in the astrocytic cytoplasm. Inspection of
the double-stained sections revealed a pattern similar to that
with ALDH1L1/GFAP double immunostaining (Figure 3),
and the results of the stereology-based quantitative analyses
reached a higher signiﬁcance level than those of the
ALDH1L1/GFAP quantiﬁcation (Figure 4). The total number
of astrocytes did not differ signiﬁcantly between non-
demented subjects and AD patients (PZ 0.8932), and did not
increase over the course of AD (rZ 0.1109, PZ 0.4958); by
contrast, the number of GSþGFAP astrocytes was signiﬁ-
cantly higher in the nondemented group (P < 0.0001) and
the number ofGSþGFAPþ astrocyteswas signiﬁcantly higher
in the AD group (P < 0.0001). Moreover, the number
of GSþGFAP astrocytes decreased as the number of
GSþGFAPþ astrocytes increased over the course of AD
(rZ 0.4870, PZ 0.0014, and rZ 0.4179, PZ 0.0073,
respectively). In fact, we observed a strong correlation2335
Figure 2 Stereology-based quantitative anal-
ysis of astrocytes double-labeled for ALDH1L1 and
GFAP. The total number of astrocytes did not differ
between AD patients and nondemented control
(CTRL) subjects (A) and remained essentially
constant through the disease clinical course (B).
The number of ALDH1L1þGFAPþ astrocytes was
higher in the AD group (E), whereas the number of
ALDH1L1þGFAP astrocytes was higher in the
nondemented group (C). Astrocytes became
increasingly reactive (GFAPþ) as the clinical phase
of the disease advances (D and F). Counts in each
case are not density measures, but estimates of
the number of cells per 1 cm-long full-width cortex
from a single section of temporal isocortex. Data
are expressed as individual values with means 
SEM (A, C, and E) or 95% conﬁdence interval of
the mean slope (B, D, and F). **P < 0.01.
Serrano-Pozo et albetween the measures of total astrocytes obtained with the
ALDH1L1/GFAP and the GS/GFAP double immunohisto-
chemistry (r Z 0.6141, P < 0.0001), and also between the
number of ALDH1L1þGFAP astrocytes and the number of
GSþGFAP astrocytes (rZ 0.8629, P < 0.0001).
Although GS is constitutively expressed in astrocytes, it
has also been reported to stain pyramidal neurons in the
cortex of AD patients.22 Indeed, we observed GSþ pyra-
midal neurons in 32 of the 40 AD specimens, typically
distributed in foci as described previously,22 but also in 19
of the 32 nondemented subjects. GSþ neurons were easy to
distinguish from GSþ astrocytes by morphological criteria.
Using our stereology-based protocol, we quantiﬁed the
number of GSþ neurons in this sample of AD and non-
demented subjects, and found a trend toward a higher
number of GSþ neurons in the AD group compared with the
nondemented group (471  110 versus 325  101 GSþ
neurons, means  SEM; P Z 0.0821). Moreover, we
observed a statistically signiﬁcant spatial association of GSþ
neurons to the vicinity (within 50 mm) of Thioﬂavin-
Sepositive dense-core plaques in the AD group (296  75
GSþ neurons close to plaques versus 175  43 GSþ neurons2336far from plaques; P Z 0.0170). Only a few of the GSþ
neurons in the AD group contained a Thioﬂavin-Sepositive
NFT (7  4 GSþThioSþ neurons).Phenotypic Change But Constant Number of Microglia
in AD
Three subtypes of microglial cells could be identiﬁed
according to their immunoreactivity in a preliminary inspec-
tion of the IBA1/MHC2 double immunohistochemistry.
IBA1þMHC2 cells were the most abundant subtype in the
temporal cortex from nondemented subjects, whereas AD
specimens had variable amounts of IBA1þMHC2þ cells.
Interestingly, some AD cases also exhibited IBA1MHC2þ
cells (Figure 5). We can assume that these cells were not
confounded with circulating mononuclear blood cells or with
perivascular macrophages, because they were located in the
midst of the neuropil (ie, notwithin a vessel or in its immediate
proximity) and had a similar morphology to that of activated
microglia. Although the nature of this third subtype awaits
further characterization (as discussed below), here we presentajp.amjpathol.org - The American Journal of Pathology
Figure 3 Confocal images of the double-ﬂuorescence immunohistochemical study of astrocytes with GS (green) (A, E, and I) and GFAP (red) (B, F, and J).
In merged images (C, G, and K), the boxed region is shown at higher magniﬁcation in the next panel (D, H, L). Representative images from three cases are
shown: one nondemented control subject (AeD) and two AD patients with 5 years (EeH) and 19 years (IeL) of clinical illness. Many astrocytes in non-
demented subjects were positive only for GS (C and D), whereas astrocytes in AD patients exhibited an increased immunoreactivity for GFAP that was
associated with the progression of the disease (G, H, K, and L). Disease-related cortical atrophy produced an increase in the density of astrocytes (eg, A versus I).
Scale bars: 50 mm (AeC, EeG, and IeK); 20 mm (D, H, and L).
Phenotypic Change of Glia in ADthe quantitative results of these three subpopulations of
microglia, as well as those of total microglia.
We have previously shown in a larger sample of AD cases
that the number of CD68þmicroglial cells is increased in AD,
compared with normal aging, and that this increase parallels
the clinical course of theADdementia and is not inﬂuenced by
APOE genotype or by cause of death.21 In the present study,
however, using the microglial markers IBA1 and MHC2, we
found that the total number of microglia did not differ
signiﬁcantly between the AD and the control groups
(PZ 0.8428) (Figure 6A), which parallels our present ﬁnd-
ings for astrocytes. Moreover, the number of total microglial
cells remained essentially unchanged through the clinical
course of the disease (rZ0.2615,PZ 0.1031) (Figure 6B).
By contrast, the number of IBA1þMHC2 microglia was
signiﬁcantly decreased (PZ 0.0239; Figure 6C), whereas the
number IBA1MHC2þ microglia was highly signiﬁcantly
increased (P < 0.0001) in the AD group (Figure 6G),
compared with the nondemented group. A statistically
nonsigniﬁcant increase in the number of IBA1þMHC2þ
microglia was also observed in the AD group (PZ 0.1417)
(Figure 6E). However, unlike astrocytes, for microglia theThe American Journal of Pathology - ajp.amjpathol.orgamount of these phenotypic subsets was not predicted by the
duration of clinical illness (Figure 6, D, F, and H).
We next studied the spatial distribution of microglial cells
with respect to dense-core, Thioﬂavin-S positive plaques
and Thioﬂavin-S positive NFTs. Based on our previous
work,21 we selected a 50-mm boundary from the closest
plaque or NFT to classify microglial cells as close or far.
The three subsets of microglial cells were similarly associ-
ated with the core pathological lesions of AD, suggesting
a similar chemoattractive behavior (P  0.0001) (Figure 7).
Several factors have been reported to inﬂuence cortical
MHC2 immunoreactivity. A long postmortem interval
(PMI) can decrease the levels of MHC2, and a death from
chronic debilitating diseases such as disseminated cancer or
sepsis, can up-regulate MHC2 in the cortex in the absence
of AD pathology.23 However, we observed no correlation
between total MHC2þ cell counts and PMI either in the AD
group (r Z 0.0972, P Z 0.5506) or the nondemented con-
trol group (r Z 0.0223, P Z 0.9049), and no signiﬁcant
differences between subjects with sudden death (typically
myocardial infarction or pulmonary embolism) and those with
protracted death (either cancer or sepsis) (data not shown).2337
**
Figure 4 Stereology-based quantitative anal-
ysis of astrocytes double-labeled for GS and GFAP.
The number of GSþGFAPþ astrocytes was higher in
the AD group (E), whereas the number of GSþGFAP
astrocytes was higher in the nondemented group
(C), but the number of total astrocytes did not
differ signiﬁcantly between AD patients and non-
demented subjects (A). This phenotypic change
paralleled the progression of the disease, but the
number of total astrocytes remained essentially
constant through its clinical course (B, D, and F).
Counts in each case are not density measures, but
estimates of the number of cells per 1 cm-long full-
width cortex from a single section of temporal iso-
cortex. Data are expressed as individual values with
means  SEM (A, C, and E) or 95% conﬁdence
interval of the mean slope (B, D, and F).
*P < 0.0001.
Serrano-Pozo et alSimilarly, we observed no effect of sex or age at death (data
not shown).
A previous study revealed an APOE ε4 allele dose-
dependent increase in MHC2 immunoreactivity in APOE
ε4 carriers, even after adjusting for the extent of AD
pathology.24 We also observed a signiﬁcantly higher total
number of IBA1þMHC2þ microglial cells (P Z 0.0061)
and a trend toward signiﬁcantly fewer IBA1þMHC2
microglial cells (P Z 0.0936) in AD patients carrying the
APOE ε4 allele, compared with noncarriers, but there was
no difference between genotypes for the subset of
IBA1MHC2þ microglia (PZ 0.6524) or for total number
of microglial cells (P Z 0.5333) (Figure 8).
Increased Density of Total Astrocytes and Microglial
Cells Is Due to Cortical Atrophy
Although our results are in agreement with numerous clas-
sical immunohistochemical studies reporting increased
GFAP and MHC2 immunoreactivity in AD, they argue
against the long-established idea that there is an actual
increase in the total numbers of astrocytes and microglial2338cells in AD. A principle of stereology is that the total number
of objects provides different information than the density of
objects, because brain atrophy by itself can lead to an artiﬁ-
cial increase in the density of the object.25We therefore asked
whether AD-related cortical atrophy possibly distorts the
perception of increased GFAP andMHC2 immunoreactivity,
thereby contributing to the idea of glial cell proliferation in
the AD brain. In the AD group, the expected cortical atrophy
was present in the temporal cortex of our AD group
(Figure 9A), and cortical atrophy was strongly correlated
with duration of clinical illness (Figure 9D). To evaluate the
effect of cortical atrophy, we compared the density measures
of astrocytes and microglial cells from the AD and non-
demented groups, instead of comparing only the cell counts
corrected by cortical thickness as above. These analyses
revealed that the densities of all astrocytes and microglial
cells were signiﬁcantly higher in AD patients, compared with
nondemented subjects. These statistically signiﬁcant results
were due mainly to expected larger differences in the
densities of GFAPþ astrocytes and MHC2þ microglia, but
also to smaller differences in the densities of GFAP astro-
cytes and MHC2 microglia (data not shown). Within theajp.amjpathol.org - The American Journal of Pathology
Figure 5 Confocal images of the double-ﬂuorescence immunohistochemical study of microglia with IBA1 (green) (A and E) and MHC2 (red) (B and F).
Representative images from a nondemented subject (AeD) and an AD patient (EeH) are shown. Also shown are merged high-power images from two different
nondemented individuals (I and J) and from two different AD patients (K and L). Thioﬂavin-S staining (blue-green) identiﬁes plaques (G, H, K, and L). The
uniform morphology and labeling of microglia in nondemented subjects contrasts with the morphological and molecular diversity of microglia in AD. Three
subpopulations of microglial cells are discernible with this double labeling: IBA1þMHC2 (arrows), IBA1þMHC2þ (arrowheads), and IBA1MHC2þ (double
arrowheads) cells. Scale bars: 50 mm (AeH); 20 mm (K and L); 10 mm (I and J).
Phenotypic Change of Glia in ADAD group, correlations with duration of clinical illness also
yielded a signiﬁcant increase of the density of all astrocytes
over the clinical course of the disease (Figure 9D), due
mainly to a stronger positive correlation of GFAPþ astro-
cytes, but also to a slightly weaker negative correlation of
GFAP astrocytes (data not shown). No signiﬁcant correla-
tion with disease duration was observed for the density of all
microglia (Figure 9D) or of any of the microglial subpopu-
lations (data not shown).
Discussion
Phenotypic Change versus Proliferation of Glial Cells
in AD
Astrocytes and microglial cells are thought to actively sense
their local environment, reacting to any injury within their
domain of inﬂuence. Whether this reaction involves gener-
ation of new glial cells remains controversial. Recently, for
example, a staging of astrocytic reaction based on GFAP
immunoreactivity has been proposed in which proliferation
is considered a feature characteristic of advanced AD, in theThe American Journal of Pathology - ajp.amjpathol.orgcontext of diffuse severe reaction and formation of compact
glial scars around amyloid plaques.12 Here, we provide
evidence suggesting that the increase in reactive glia in the
AD brain is due largely to a phenotypic change of existing
resting glial cells, rather than to generation of new glial cells
from glial precursors. Two technical features particular to
the present study enabled us to reach this conclusion: one is
the use of double-ﬂuorescence immunohistochemistry com-
bining antibodies against constitutive and activation markers
of astrocytes and microglia, rather than the standard single-
antibody immunohistochemistry for the classical markers of
reactive glia, GFAP and MHC2; the other is the use of
stereology-based quantitative methods, including systematic
and random sampling of the specimens to avoid observer
bias, and estimation of cell counts corrected by cortical
atrophy rather than density measures, which can be artiﬁ-
cially enhanced in the context of a reduced volume of
cortex.25
The evidence for generation of new glial cells in AD is
conﬂicting. A previous stereology-based human postmortem
study using Nissl staining for neurons and analyzing the
morphology of the stained cells revealed no difference in the2339
Figure 6 Stereology-based quantitative anal-
ysis of microglia double-labeled for IBA1 and
MHC2. The total number of microglia did not differ
signiﬁcantly between the nondemented and the
AD groups (A). Within the AD group, neither total
microglial cells (B) nor any of the microglia
subtypes (D, F, and H) was observed to increase
with the clinical progression of the disease.
However, IBA1þMHC2 microglia (C) was signiﬁ-
cantly more abundant in the nondemented group,
and IBA1MHC2þ microglia (G) were signiﬁcantly
more abundant in the AD. There was a trend
toward increase in IBA1þMHC2þ microglia in the
AD group (E). Counts in each case are not density
measures, but estimates of the number of cells per
1 cm-long full-width cortex from a single section
of temporal isocortex. Data are expressed as
individual values with means  SEM (A, C, E, and
G) or 95% conﬁdence interval of the mean slope
(B, D, F, and H).*P < 0.05, yP < 0.0001.
Serrano-Pozo et alnumber of astrocytes and microglial cells in AD, compared
with age-matched nondemented individuals.26 Reports of
other studies, however, have described an increased
expression of cell division markers, including Ki-67 and
cyclins, by astrocytes in the AD brain27e29 and in an APP-
overexpressing mouse model.30 More dynamic animal
studies with injections of bromodeoxyuridine have shown
that the number of bromodeoxyuridine-positive glial cells is
increased in APP transgenic mice, compared with their
wild-type littermates, particularly in the vicinity of plaques,
and the majority of these bromodeoxyuridine-positive cells
were identiﬁed as microglia, rather than astrocytes.31e332340Given the cross-sectional design inherent to any neuro-
pathological study, the ﬁnding of similar total numbers of
astrocytes and microglial cells in AD patients and non-
demented subjects could also be explained by a balance
between cell proliferation and death. However, this possi-
bility seems less likely, because we noticed a wide range of
intermediate phenotypes in individual glial cells with our
double-ﬂuorescent stainings, ranging from no GFAP or
MHC2 immunoreactivity to very intense immunoreactivity
(Figures 1, 3, and 5), favoring the idea of phenotypic
change, and also because we failed to observe a signiﬁcant
positive ﬂuorescent staining with the mitotic marker Ki-67ajp.amjpathol.org - The American Journal of Pathology
*
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Figure 7 Association of the three microglial subpopulations with dense-
core plaques andNFTs. The randomly selectedmicroglial cells were categorized
as close if located within 50 mm from the closest dense-core plaque or NFT, or
as far if located more than 50 mm away from it. The three subsets of microglial
cells are similarly attracted by the pathological hallmarks of AD and recruited
toward them. Counts in each case are not density measures, but estimates of
the number of cells per 1 cm-long full-width cortex from a single section of
temporal isocortex. Counts close and far (from AD pathological hallmarks)
from each of the 40 AD subjects are connected with lines. *P < 0.0001.
Figure 9 Effect of cortical atrophy on density measures of astrocytes and
microglia. A: As expected, the quantiﬁcation of cortical thickness of the
temporal isocortex (Brodmann area 38) in the study subjects revealed
signiﬁcant cortical atrophy in the AD group, comparedwith the nondemented
group. B and C: Unlike total numbers (Figures 2, 4, and 6), densities of total
astrocytes (B) and total microglial cells (C) were signiﬁcantly increased in the
AD group, compared with the nondemented group. D: In the AD group,
cortical thickness (right y axis and regression line with shaded error bars)
correlated negatively with duration of clinical illness (r Z 0.6538, P <
0.0001), indicating that disease duration is a reliable proxy of dementia
severity. Unlike the total number of astrocytes (Figures 2 and 4), density (left
y axis) of all astrocytes (solid symbols) correlated positively with disease
duration (rZ 0.6400, P< 0.0001), because of progressive cortical atrophy;
however, density of all microglia (open symbols) did not correlate signiﬁ-
cantly with disease duration (rZ 0.0982, PZ 0.5466). The 95% conﬁdence
interval (open error bars) of the mean slope is indicated. Data used to build
the cortical thickness regression line for these 40 AD patients were drawn
21 y
Phenotypic Change of Glia in ADin both the AD and nondemented subjects, whether in the
temporal neocortex or in the hippocampus (Supplemental
Figure S1). Although Ki-67 is widely used to assess the
proliferative capacity of brain tumors, the number of posi-
tive cells in the normal or AD brain at any given momentFigure 8 Effect of the APOE ε4 allele on microglial phenotype. Numbers
of total microglia (A), IBA1þMHC2 microglia (B), and IBA1MHC2þ
microglia (D) did not differ between APOE ε4 carriers and noncarriers. Only
for IBA1þMHC2þ microglia (C) were numbers signiﬁcantly higher in APOE
ε4 carriers, compared with noncarriers. Counts in each case are not density
measures, but estimates of the number of cells per 1 cm-long full-width
cortex from a single section of temporal isocortex. Data are expressed as
individual values with means  SEM. *P < 0.01.
from Serrano-Pozo et al. *P < 0.05, P < 0.0001.
The American Journal of Pathology - ajp.amjpathol.orgmay be too low and therefore this approach would require
an exhaustive and time-consuming sampling of the entire
brain.
Implications for the Role of Glia in AD
The distinction between phenotypic change and prolifera-
tion as contributors to glial reactions is not merely semantic,
but has relevant pathophysiological implications. We have
recently shown that the number of GFAPþ astrocytes and
CD68þ microglial cells in the temporal neocortex increases
linearly through the clinical course of AD and parallels the
increasing number of NFTs, whereas amyloid plaque burden
remains relatively stable.21 We also observed that this
reactive glia accumulates in the proximity of both dense-
core plaques and NFTs.21 In addition, it has been reported
that the number of GFAPþ astrocytes correlates with the
Braak stage of NFTs,34 and we and other researchers have
shown that cortical GFAP levels measured by enzyme-
linked immunosorbent assay correlate with indicators of
disease progression, such as duration of clinical disease20
and cognitive measures.35 Although this evidence can be
interpreted simply as a protective reaction of glial cells to2341
Serrano-Pozo et althe ongoing neurodegenerative process, another possible
interpretation is that reactive glia in fact contributes to the
synaptic and neuronal damage that underlies cognitive
impairment in AD.36 Both astrocytes and microglia have
been recently shown to be involved in the normal devel-
opment of synapses and neuronal circuits during postnatal
brain development,37e39 and they may play an active role in
neurodegeneration as well.40e43 Thus, understanding and
manipulating the intimate molecular mechanisms respon-
sible for this phenotypic change should help to elucidate
whether glia in AD is protective, is deleterious, or has a dual
role.
The identiﬁcation of a subpopulation of IBA1MHC2þ
microglia using double immunoﬂuorescence must be inter-
preted in the context of what is known about the expression of
these markers. IBA1 is thought to be constitutively expressed
in resting microglial cells and to become up-regulated on
microglial activation.9 Activated microglia shares expression
ofMHC2with bloodmononuclear cells, and it is possible that
some of the IBA1MHC2þ cells counted were not actually
microglial cells but instead were monocytes, lymphocytes, or
perivascular macrophages. This explanation seems unlikely,
however, because care was taken to exclude positive cells
within blood vessels or immediately adjacent to them [ie,
perivascular macrophages, known to be MHC-positive44,45],
because only cells with evident cytoplasmic processes such as
those of microglia were included in the counting, and because
most of these cells were intimately associated with dense-core
plaques (Figures 5 and 7D). It is possible that IBA1MHC2þ
cells are indeed peripheral blood cells recruited to the brain
parenchyma and modiﬁed toward a microglial phenotype.
Whether bone marrowederived circulating mononuclear
phagocytes can cross the bloodebrain barrier is a matter of
intense research and controversy. Studies in plaque-bearing
mice models of AD involving whole-body irradiation and
transplantation of labeled bone-marrow hematopoietic pre-
cursors revealed that these transplanted cells readily enter in
the brain and contribute to plaque clearance.46e48 However,
a more recent study comparing whole-body irradiation versus
an irradiation protocol with protection of the head has shown
that the integrity of the bloodebrain barrier may have been
compromised by the head irradiation in these prior studies.49
On the other hand, as suggested by postmortem immunohis-
tochemical studieswith antibodies against plasmaproteins50e52
and by an increased cerebrospinal ﬂuid/plasma albumin
ratio,53e55 the integrity of the bloodebrain barrier may be
impaired in AD patients, compared with age-matched control
subjects, and this disruption may be severe enough to facilitate
not only the leakageof plasmaproteins to thebrainparenchyma,
but also the recruitment of circulating blood mononuclear
phagocytes.
Likewise interesting is the ﬁnding that, compared with
noncarriers, AD APOE ε4 carriers had signiﬁcantly more
IBA1þMHC2þ microglia, but similar total numbers of mic-
roglial cells. Egensperger et al24 had already reported this
increased MHC2 immunoreactivity in APOE ε4 carriers in23421998, and showed that it is independent of the amount of AD
pathology. Recent studies have suggested that Apo-E iso-
forms may differentially inﬂuence the innate immune res-
ponse, with Apo-E4 causing reduced microglial migration56
and increased proinﬂammatory activation,57,58 compared
with Apo-E3. Further studies are needed to address the role of
Apo-E in microglial expression of MHC2 in AD.
Implications for Imaging Biomarkers of AD
Our ﬁndings also have potential implications for develop-
ment of imaging diagnostic biomarkers. They provide both
a rationale and a methodological basis for validation of
molecular targets of glia-directed positron emission tomog-
raphy (PET) radiotracers in postmortem brains. Although it is
clear that only radiotracers that target glial receptors speciﬁ-
cally up-regulated in cells with the reactive phenotype will be
clinically useful as diagnostic and progression biomarkers of
AD, the development of glia-directed PET radiotracers has
proved to be very challenging. The peripheral benzodiazepine
receptor [PBR; alias 18-kDa translocator protein (TSPO)]
is considered the preferred molecular target of reactive
glia,59e61 but the ﬁrst TSPO-directed radiotracer, [11C](R)-
PK11195, has largely failed to distinguish between AD
patients and cognitively intact elderly people.62,63
In summary, our results indicate that the higher immu-
noreactivity observed in AD brain with the classical markers
widely used for astrocytes and microglial cells reﬂects
a change in phenotype more than an increase in the absolute
number of these cells. Thus, we conclude that both astro-
cytic and microglial reactions in AD are due largely to
a phenotypic change of existing resting glial cells, rather
than to a generation of new glial cells from glial precursors.
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